{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:19:24Z","timestamp":1788477564370,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81971463"],"award-info":[{"award-number":["81971463"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Guangdong Province","award":["2025A1515010410"],"award-info":[{"award-number":["2025A1515010410"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The tumor immune microenvironment critically influences progression and therapeutic response in intrahepatic cholangiocarcinoma (ICC). MYBL2 drives tumor aggressiveness, while CCL5 regulates immune-cell recruitment; however, their combined impact on immune composition and PD-1 therapy response remains undefined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Tumor specimens from 127 ICC patients were assessed by immunohistochemistry and whole-slide digital quantification. MYBL2 and CCL5 expression were classified into four combinatorial phenotypes. Associations with immune-cell infiltration, survival, and treatment response were evaluated using correlation analysis, Kaplan\u2013Meier curves, Cox regression, and PD-1 interaction analyses. Seventy patients received adjuvant PD-1 therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MYBL2 and CCL5 expression were positively correlated (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.38,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Higher CCL5 levels were associated with increased CD163\u207a TAM density (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.31,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and a reduced CD8\/CD163 ratio, indicating an immunosuppressive microenvironment. The MYBL2\u2013CCL5 classification provided clear prognostic discrimination, with the Double-High subgroup showing the shortest OS and PFS. Among PD-1\u2013treated patients, treatment benefit varied markedly across phenotypes: the Double-Low group achieved the greatest survival advantage, whereas the Double-High group showed minimal response, reflecting primary resistance. In multivariable analysis, Double-Low remained strongly protective compared with Double-High.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The MYBL2\u2013CCL5 co-expression phenotype identifies an immunosuppressive, TAM-dominant microenvironment and serves as a dual biomarker for both prognosis and PD-1 treatment sensitivity in ICC. This immunologic classification offers a practical framework for postoperative risk stratification and personalized immunotherapy decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16219-4","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:44:08Z","timestamp":1781682248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Correlated expression of MYBL2 and CCL5 defines an immunosuppressive microenvironment and predicts poor prognosis in intrahepatic cholangiocarcinoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Junkai","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sicheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"9","key":"16219_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"16219_CR2","doi-asserted-by":"publisher","first-page":"101936","DOI":"10.1016\/j.ctrv.2019.101936","volume":"84","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Edeline J, McNamara MG, Hubner RA, Nagino M, Bridgewater J, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat Rev. 2020;84:101936.","journal-title":"Cancer Treat Rev"},{"key":"16219_CR3","doi-asserted-by":"publisher","first-page":"1451474","DOI":"10.3389\/fimmu.2024.1451474","volume":"15","author":"F Chen","year":"2024","unstructured":"Chen F, Sheng J, Li X, Gao Z, Hu L, Chen M, et al. Tumor-associated macrophages: orchestrators of cholangiocarcinoma progression. Front Immunol. 2024;15:1451474.","journal-title":"Front Immunol"},{"issue":"1","key":"16219_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/hep.31410","volume":"73","author":"L Fabris","year":"2021","unstructured":"Fabris L, Sato K, Alpini G, Strazzabosco M. The Tumor Microenvironment in Cholangiocarcinoma Progression. Hepatology. 2021;73(1):75\u201385.","journal-title":"Hepatology"},{"key":"16219_CR5","doi-asserted-by":"publisher","first-page":"103375","DOI":"10.1016\/j.ebiom.2021.103375","volume":"67","author":"M Zhou","year":"2021","unstructured":"Zhou M, Wang C, Lu S, Xu Y, Li Z, Jiang H, Ma Y. Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target. EBioMedicine. 2021;67:103375.","journal-title":"EBioMedicine"},{"issue":"2","key":"16219_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41389-021-00309-y","volume":"10","author":"Y Cicir\u00f2","year":"2021","unstructured":"Cicir\u00f2 Y, Sala A. MYB oncoproteins: emerging players and potential therapeutic targets in human cancer. Oncogenesis. 2021;10(2):19.","journal-title":"Oncogenesis"},{"issue":"12","key":"16219_CR7","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.tibs.2022.06.007","volume":"47","author":"M Fischer","year":"2022","unstructured":"Fischer M, Schade AE, Branigan TB, M\u00fcller GA, DeCaprio JA. Coordinating gene expression during the cell cycle. Trends Biochem Sci. 2022;47(12):1009\u201322.","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"16219_CR8","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1186\/s12885-022-10354-4","volume":"22","author":"JZ Zhao","year":"2022","unstructured":"Zhao JZ, Wang W, Liu T, Zhang L, Lin DZ, Yao JY, et al. MYBL2 regulates de novo purine synthesis by transcriptionally activating IMPDH1 in hepatocellular carcinoma cells. BMC Cancer. 2022;22(1):1290.","journal-title":"BMC Cancer"},{"key":"16219_CR9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.2147\/OTT.S555199","volume":"18","author":"CC Chen","year":"2025","unstructured":"Chen CC, Wei CT, Hsuan CF, Yu TH, Hung WC, Wu CC, et al. Clinical Significance of MYBL2 Expression in Hepatocellular Carcinoma: Impact on Overall Survival. Onco Targets Ther. 2025;18:1353\u201362.","journal-title":"Onco Targets Ther"},{"key":"16219_CR10","doi-asserted-by":"publisher","first-page":"1595485","DOI":"10.3389\/fonc.2025.1595485","volume":"15","author":"J Lu","year":"2025","unstructured":"Lu J, Luo FMYB, Proto-Oncogene. Like 2 identified as a biomarker for uterine corpus endometrial carcinoma: evidence from bioinformatics and clinical validation. Front Oncol. 2025;15:1595485.","journal-title":"Front Oncol"},{"issue":"3","key":"16219_CR11","doi-asserted-by":"publisher","first-page":"101004","DOI":"10.1016\/j.gendis.2023.04.035","volume":"11","author":"X Qiu","year":"2024","unstructured":"Qiu X, He H, Zeng H, Tong X, Zhang C, Liu Y, et al. Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration. Genes Dis. 2024;11(3):101004.","journal-title":"Genes Dis"},{"issue":"2","key":"16219_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41416-025-03253-5","volume":"134","author":"J Pei","year":"2026","unstructured":"Pei J, Fan J, Liao Y, Li M, Bai X, Wang Y, et al. Prognostic value of MYBL2 and its potential implications for immunotherapy: a study of bioinformatics and experimental validation. Br J Cancer. 2026;134(2):317\u201330.","journal-title":"Br J Cancer"},{"issue":"11","key":"16219_CR13","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1158\/0008-5472.CAN-16-2913","volume":"77","author":"Y Ban","year":"2017","unstructured":"Ban Y, Mai J, Li X, Mitchell-Flack M, Zhang T, Zhang L, et al. Targeting Autocrine CCL5-CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity. Cancer Res. 2017;77(11):2857\u201368.","journal-title":"Cancer Res"},{"key":"16219_CR14","doi-asserted-by":"crossref","unstructured":"Zilio S, Bicciato S, Weed D, Serafini P. CCR1 and CCR5 mediate cancer-induced myelopoiesis and differentiation of myeloid cells in the tumor. J Immunother Cancer. 2022;10(1):e003131.","DOI":"10.1136\/jitc-2021-003131"},{"issue":"1","key":"16219_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12935-023-03079-2","volume":"23","author":"B Pan","year":"2023","unstructured":"Pan B, Wan T, Zhou Y, Huang S, Yuan L, Jiang Y, et al. The MYBL2-CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages. Cancer Cell Int. 2023;23(1):248.","journal-title":"Cancer Cell Int"},{"key":"16219_CR16","doi-asserted-by":"crossref","unstructured":"Chen H, Jin Z, Peng Y, Li Y, Li Z, Zhang X, et al. Malevolent alliance of MYBL2(hi) cancer stem cell and SPP1\u2009+\u2009macrophage confers resistance to neoadjuvant immunotherapy in bladder cancer. J Immunother Cancer. 2025;13(7):e011319.","DOI":"10.1136\/jitc-2024-011319"},{"key":"16219_CR17","doi-asserted-by":"publisher","first-page":"871769","DOI":"10.3389\/fimmu.2022.871769","volume":"13","author":"BY Sun","year":"2022","unstructured":"Sun BY, Zhou C, Guan RY, Liu G, Yang ZF, Wang ZT, et al. Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic Cholangiocarcinoma via Single-Cell Analysis. Front Immunol. 2022;13:871769.","journal-title":"Front Immunol"},{"issue":"10","key":"16219_CR18","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1172\/JCI137110","volume":"130","author":"E Loeuillard","year":"2020","unstructured":"Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy C, et al. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest. 2020;130(10):5380\u201396.","journal-title":"J Clin Invest"},{"issue":"2","key":"16219_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/cancers4020549","volume":"4","author":"M Di Maio","year":"2012","unstructured":"Di Maio M, Daniele G, Piccirillo MC, Giordano P, Signoriello G, Daniele B, Perrone F. Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials. Cancers (Basel). 2012;4(2):549\u201365.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"16219_CR20","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41416-018-0281-9","volume":"119","author":"A Maity","year":"2018","unstructured":"Maity A, Mick R, Huang AC, George SM, Farwell MD, Lukens JN, et al. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. Br J Cancer. 2018;119(10):1200\u20137.","journal-title":"Br J Cancer"},{"key":"16219_CR21","doi-asserted-by":"crossref","unstructured":"Bazzichetto C, Luchini C, Conciatori F, Vaccaro V, Di Cello I, Mattiolo P, et al. Morphologic and molecular landscape of pancreatic cancer variants as the basis of new therapeutic strategies for precision oncology. Int J Mol Sci. 2020;21(22):8841.","DOI":"10.3390\/ijms21228841"},{"key":"16219_CR22","doi-asserted-by":"publisher","first-page":"107327482413052","DOI":"10.1177\/10732748241305237","volume":"31","author":"J Jin","year":"2024","unstructured":"Jin J, Mou H, Zhou Y, Zhang S. Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers. Cancer Control. 2024;31:10732748241305237.","journal-title":"Cancer Control"},{"key":"16219_CR23","doi-asserted-by":"crossref","unstructured":"Files R, Okwu V, Topa N, Sousa M, Silva F, Rodrigues P, et al. Assessment of Tumor-Associated Tissue Eosinophilia (TATE) and Tumor-Associated Macrophages (TAMs) in canine transitional cell carcinoma of the urinary bladder. Anim (Basel). 2024;14(3):519.","DOI":"10.3390\/ani14030519"},{"issue":"5","key":"16219_CR24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.molmed.2018.03.006","volume":"24","author":"JL Guerriero","year":"2018","unstructured":"Guerriero JL, Macrophages. The Road Less Traveled, Changing Anticancer Therapy. Trends Mol Med. 2018;24(5):472\u201389.","journal-title":"Trends Mol Med"},{"issue":"12","key":"16219_CR25","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","volume":"17","author":"L Cassetta","year":"2018","unstructured":"Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887\u2013904.","journal-title":"Nat Rev Drug Discov"},{"issue":"13","key":"16219_CR26","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1158\/1078-0432.CCR-16-3122","volume":"23","author":"JM Brown","year":"2017","unstructured":"Brown JM, Recht L, Strober S. The Promise of Targeting Macrophages in Cancer Therapy. Clin Cancer Res. 2017;23(13):3241\u201350.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"16219_CR27","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1158\/1078-0432.CCR-16-0133","volume":"23","author":"DF Quail","year":"2017","unstructured":"Quail DF, Joyce JA. Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies. Clin Cancer Res. 2017;23(4):876\u201384.","journal-title":"Clin Cancer Res"},{"issue":"6024","key":"16219_CR28","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612\u20136.","journal-title":"Science"},{"issue":"12","key":"16219_CR29","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1016\/j.celrep.2016.05.058","volume":"15","author":"KT Byrne","year":"2016","unstructured":"Byrne KT, Vonderheide RH. CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Rep. 2016;15(12):2719\u201332.","journal-title":"Cell Rep"},{"issue":"12","key":"16219_CR30","doi-asserted-by":"publisher","first-page":"10399","DOI":"10.18632\/oncotarget.3295","volume":"6","author":"A Lonetti","year":"2015","unstructured":"Lonetti A, Cappellini A, Spart\u00e0 AM, Chiarini F, Buontempo F, Evangelisti C, et al. PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. Oncotarget. 2015;6(12):10399\u2013414.","journal-title":"Oncotarget"},{"issue":"15suppl","key":"16219_CR31","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1200\/JCO.2018.36.15_suppl.3013","volume":"36","author":"RJ Sullivan","year":"2018","unstructured":"Sullivan RJ, Hong DS, Tolcher AW, Patnaik A, Shapiro G, Chmielowski B, et al. Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. J Clin Oncol. 2018;36(15suppl):3013.","journal-title":"J Clin Oncol"},{"issue":"4","key":"16219_CR32","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","volume":"182","author":"M Molgora","year":"2020","unstructured":"Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, et al. TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy. Cell. 2020;182(4):886\u2013e90017.","journal-title":"Cell"},{"issue":"10","key":"16219_CR33","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1158\/0008-5472.CAN-16-2534","volume":"77","author":"RJ Davis","year":"2017","unstructured":"Davis RJ, Moore EC, Clavijo PE, Friedman J, Cash H, Chen Z, et al. Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kdelta\/gamma. Cancer Res. 2017;77(10):2607\u201319.","journal-title":"Cancer Res"},{"key":"16219_CR34","doi-asserted-by":"crossref","unstructured":"Jahchan NS, Binnewies M, Pollack JL, Mehta R, Dash S, Tun C, et al. Abstract LB071: Tuning the tumor myeloid microenvironment (TME) by targeting TREM2\u2009+\u2009tumor-associated macrophages to overcome resistance to immune checkpoint inhibitors. Clinical Research (Excluding Clinical Trials; 2021.","DOI":"10.1158\/1538-7445.AM2021-LB071"},{"issue":"14","key":"16219_CR35","doi-asserted-by":"publisher","first-page":"18508","DOI":"10.18632\/oncotarget.7610","volume":"7","author":"NM Luheshi","year":"2016","unstructured":"Luheshi NM, Coates-Ulrichsen J, Harper J, Mullins S, Sulikowski MG, Martin P, et al. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget. 2016;7(14):18508\u201320.","journal-title":"Oncotarget"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16219-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16219-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16219-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:51:22Z","timestamp":1788475882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16219-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16219"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16219-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was reviewed and approved by the Ethics Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University (Approval No. SYSKY-2025-513-01). Owing to the retrospective study design and the use of anonymized clinical data, the requirement for informed consent was waived by the Ethics Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University. All procedures were conducted in accordance with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1053"}}